European Primary Care Cardiovascular Society

Diabetes

Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.
EPCCS Annual CV Summit

Update on managing CV risk in diabetes: what's the evidence?

5' education - Mar. 22, 2019 - Lisbon, Portugal - Kamlesh Khunti & Richard Hobbs

EPCCS

3' education - Feb. 8, 2019

The cardiovascular challenge for primary care in diabetes

10' education - July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

Consideration of SGLT2 inhibitor treatment in broader T2DM population

3' education - Nov. 26, 2018 - Steve Wiviott, MD - Boston, MA, VS.

CV safety with weight loss agent in high-risk overweight or obese patients

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No overall benefit with aspirin in a primary prevention setting of diabetes patients

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

Omega-3 fatty acid supplements do not result in CV benefits

3' education - Aug. 26, 2018 - Dr Louise Bowman, Oxford, UK
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - July 17, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (2/3)

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - July 12, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Management of CV risk that comes with T2DM in light of novel treatment options

10' education - Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Carlos Brotons, prof. Xavier Cos, prof. Richard Hobbs

Striking results for weight reduction in T2DM in primary care based program

3' education - Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK

The evidence base for health behaviour changes

10' education - Dec. 9, 2015 - EPCCS 2015 - Prague, Czech Republic

What's the evidence for BP and lipid targets in diabetes?

3' education - Nov. 25, 2014 - EPCCS 2014, Brussels
##SCROLLER_ITEMS_FULL_TITLE##

Future developments in treating hyperglycemia in type 2 diabetes

3' education - Sep. 20, 2013 - London, 5-6 September 2013 - Neil Munro

Original intensive glucose control does not result in CV benefit in T2DM after 15 years: no legacy effect

Literature - June 25, 2019 - Reaven PD, et al. - N Eng J Med 2019

In a follow-up study of VADT, original intensive glucose lowing over 5.6 years did not result in improved outcomes in T2DM patients vs. standard-therapy after 15 years, providing no evidence of a legacy effect.

Update on managing CV risk in diabetes: what's the evidence?

5' education - Mar. 22, 2019 - Lisbon, Portugal - Kamlesh Khunti & Richard Hobbs
Profs Khunti and Hobbs discuss why CV risk needs attention in patients with diabetes, and how this risk can be mitigated. They also consider barriers that prevent optimal implementation of the evidence on effective management strategies.

EPCCS 2019 Profs Khunti and Hobbs discuss why CV risk needs attention in patients with diabetes, and how this can be mitigated. They also consider barriers that prevent optimal implementation of the evidence on effective management strategies.

Benefit of intensive BP lowering in adults with diabetes seems independent of baseline BP

Literature - May 20, 2019 - Rahman F T et al.. - Hypertension. 2019

An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.

Education, exchange, guidance and interaction during EPCCS Summit 2019

EPCCS Annual CV Summit

EPCCS 2019 Read impressions of the updates on stroke prevention in AF, hypertension, HF and CV risk in diabetes, with emphasis on challenges faced in patients with multimorbidities.

Slides | What's the evidence that diabetes is linked to CVD risk?

Slides (presentation) - Mar. 22, 2019 - Prof. Richard Hobbs
**EPCCS 2019** Slides prepared and presented by prof. **Richard Hobbs** (Oxford, United Kingdom), here offered as an educational service.

EPCCS 2019 Slides prepared and presented by prof. Richard Hobbs (Oxford, United Kingdom), here offered as an educational service.

Slides | Diabetes and cardiovascular risk

Slides (presentation) - Mar. 22, 2019 - Lisbon, Portugal - Prof. Kamlesh Khunti
**EPCCS 2019** Slides prepared and presented by prof. **Kamlesh Khunti** (Leicester, UK) here offered as an educational service.

EPCCS 2019 Slides prepared and presented by prof. Kamlesh Khunti (Leicester, UK) here offered as an educational service.

Diabetes and cardiovascular risk

EPCCS Annual CV Summit

EPCCS 2019 Prof. Hobbs set the scene for the presentation of prof. Khunti, by showing how diabetes is linked to CVD risk, after which prof. Khunti outlined how this risk can best be reduced with therapy.

A patient-centered approach in new ACC/AHA primary prevention guideline

News - Mar. 20, 2019

ACC 2019 The new guideline promotes a healthy lifestyle throughout life, and encourages physicians to assess social determinants of health to optimally implement the recommendations.

Trends, treatment and control of CV risk factors for women vs men in the US from 2001-2016

Literature - Mar. 6, 2019 - Peters SA, et al. - Circulation 2019

A study with representative US citizens showed similar trends for most CV risk factors between men and women from 2001 to 2016, with the exception of BMI and total cholesterol, and sex differences for control of hypertension, diabetes and dyslipidemia.

Current management of diabetes and cardiovascular risk in primary care

Scroll down to download a free copy

Download - EPCCS Consensus Guidance for Primary Care
EPCCS Consensus Guidance for Primary Care

Download the EPCCS Practical Guidance Document, which provides a brief scientific background on the need for and practical guidance on management of hyperglycaemia and the increased CV risk in patients with type 2 diabetes. The document focusses on challenges faced in clinical reality.

Efficacy of statins in primary CVD prevention confirmed in large meta-analysis, but individual benefit-harm profiles vary

Literature - Feb. 19, 2019 - Yebyo HG et al. - Am Heart J 2019

This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.

EPCCS

European Primary Care Cardiovascular Society

3' education - Feb. 8, 2019

Learn more about the activities of EPCCS that are aimed at supporting primary care professionals manage their patients with cardiovascular and cardiometabolic disease.